Out-of-Pocket Cost of Spinal Muscular Atrophy Gene Therapies Among Commercially Insured Patients

Key Points

• To assess the insurance coverage and out-of-pocket costs associated with spinal muscular atrophy gene therapies.
• Cross-sectional study design
• Evaluation of commercial insurance data
• Analysis of patient spending from 2021-2022
• Overall out-of-pocket costs for patients using SMA therapies were substantial
• Variations in costs were observed across different therapies
• Insurance coverage significantly influenced patient expenditure

Abstract